These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34279604)

  • 21. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and Associated Stroke Risk of Human Immunodeficiency Virus-Infected Patients With Atrial Fibrillation　- A Nationwide Cohort Study.
    Jung H; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Sung JH; Pak HN; Lee MH; Lip GYH; Joung B
    Circ J; 2019 Nov; 83(12):2547-2554. PubMed ID: 31619594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.
    Fauchier L; Lecoq C; Clementy N; Bernard A; Angoulvant D; Ivanes F; Babuty D; Lip GY
    Chest; 2016 Apr; 149(4):960-8. PubMed ID: 26425935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and predictors of hospitalization in patients with atrial fibrillation: results from the Chinese atrial fibrillation registry study.
    Dong Z; Du X; Lu S; Jiang C; Xia S; He L; Su X; Jia Z; Long D; Sang C; Tang R; Liu N; Bai R; Yu R; Dong J; Ma C
    BMC Cardiovasc Disord; 2021 Mar; 21(1):146. PubMed ID: 33740910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF.
    Verheugt FWA; Ambrosio G; Atar D; Bassand JP; Camm AJ; Costabel JP; Fitzmaurice DA; Illingworth L; Goldhaber SZ; Goto S; Haas S; Jansky P; Kayani G; Stepinska J; Turpie AGG; van Eickels M; Kakkar AK;
    Am J Med; 2019 Dec; 132(12):1431-1440.e7. PubMed ID: 31306621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atrial fibrillation and upper limb thromboembolectomy: a national cohort study.
    Andersen LV; Mortensen LS; Lip GY; Lindholt JS; Faergeman O; Henneberg EW; Frost L
    J Thromb Haemost; 2011 Sep; 9(9):1738-43. PubMed ID: 21736696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study.
    Giustozzi M; Vedovati MC; Verso M; Scrucca L; Conti S; Verdecchia P; Bogliari G; Pierpaoli L; Agnelli G; Becattini C
    Int J Cardiol; 2019 Apr; 281():56-61. PubMed ID: 30712846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ischemic Stroke and Transient Ischemic Attack Risk Following Vitamin K Antagonist Cessation in Newly Diagnosed Atrial Fibrillation: A Cohort Study.
    Martinez C; Wallenhorst C; Rietbrock S; Freedman B
    J Am Heart Assoc; 2020 Jan; 9(2):e014376. PubMed ID: 31937194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Causes of death and influencing factors of atrial fibrillation patients undergoing anticoagulation therapy].
    Hua C; Jiang C; He L; Jia ZX; Lyu WH; Tang RB; Sang CH; Long DY; Dong JZ; Ma CS; Du X
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Apr; 49(4):353-359. PubMed ID: 33874685
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
    Jones WS; Hellkamp AS; Halperin J; Piccini JP; Breithardt G; Singer DE; Fox KA; Hankey GJ; Mahaffey KW; Califf RM; Patel MR
    Eur Heart J; 2014 Jan; 35(4):242-9. PubMed ID: 24302273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors.
    Pastori D; Pignatelli P; Angelico F; Farcomeni A; Del Ben M; Vicario T; Bucci T; Raparelli V; Cangemi R; Tanzilli G; Lip GYH; Violi F
    Chest; 2015 Jun; 147(6):1644-1650. PubMed ID: 25429521
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.